Immunoexpression of SDHB, FH, and CK20 among eosinophilic renal tumors: A tissue microarray study.

Karatay H., Ozluk Y., Dogan M. A., Erdem S., Kilicaslan I.

Annals of diagnostic pathology, vol.54, pp.151788, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 54
  • Publication Date: 2021
  • Doi Number: 10.1016/j.anndiagpath.2021.151788
  • Journal Name: Annals of diagnostic pathology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.151788
  • Keywords: Succinate dehydrogenase B, Cytokeratin 20, Fumarate hydratase, Eosinophilic renal tumors, Succinate dehydrogenase-deficient renal cell carcinoma, Eosinophilic, solid, and cystic renal cell carcinoma, SUCCINATE-DEHYDROGENASE B, CELL CARCINOMA, HEREDITARY LEIOMYOMATOSIS, GERMLINE SDHB, PHEOCHROMOCYTOMA, MUTATIONS, IMMUNOHISTOCHEMISTRY, PARAGANGLIOMAS, CLASSIFICATION, SUBTYPE
  • Istanbul University Affiliated: Yes


Background: Differential diagnosis can be a challenge for eosinophilic subtypes of renal cell tumors due to their overlapping histomorphological and immunohistochemical features. We aimed to investigate the frequency of rare variants of renal cell carcinomas (RCCs) such as succinate dehydrogenase-deficient RCC (SDDRCC), hereditary leiomyomatosis and RCC (HLRCC)-associated RCC, and eosinophilic, solid, and cystic RCC (ESCRCC) in our population. Materials and methods: Renal tumors which could be considered in the eosinophilic tumor category were included: 91 conventional clear cell RCCs with eosinophilic cytoplasm, 72 papillary RCCs, 74 chromophobe RCCs, 88 oncocytomas, and 37 other rare subtypes. Using the tissue microarray method, succinate dehydrogenase B (SDHB), fumarate hydratase (FH), and cytokeratin 20 (CK20) antibodies were performed by immunohistochemistry. Immunohistochemistry was repeated on whole block sections for selected cases. The utility of these antibodies in the differential diagnosis was also investigated. Results: Loss of SDHB expression was detected in three tumors, two of which showed typical morphology for SDDRCC. In additional two tumors, SDHB showed weak cytoplasmic expression without a mitochondrial pattern (possible-SDHB deficient). None of the tumors showed loss of FH expression. Heterogeneous reactions were observed with SDHB and FH antibodies. Only one ESCRCC was detected with diffuse CK20 positivity. Conclusion: SDDRCCs, HLRCC-associated RCCs, and ESCRCCs are very rare tumors depending on the population. Possible weak staining and focal loss of SDHB and FH expression should be kept in mind and genetic testing must be included for equivocal results.